Literature DB >> 7284572

Selected ion monitoring of metoprolol and two metabolites in plasma and urine using deuterated internal standards.

M Ervik, K J Hoffmann, K Kylberg-Hanssen.   

Abstract

A highly sensitive and specific quantitative assay for metoprolol and two of its metabolites, containing an unchanged 2-hydroxy-4-isopropylaminopropoxy sidechain, has been developed. The compounds are isolated from the alkalized sample (plasma or urine) by extraction with dichloromethane, and converted to trifluoroacetyl derivatives by reaction with methyl-bis-(trifluoroacetamide). The reaction mixture is gas chromatographed on an OV-17 column and each substance is assayed by electron impact mass spectrometry using selected ion monitoring, and quantified by comparing the intensity of fragment ion m/z 266 with the intensities of corresponding fragment ions from the deuterated internal standards (m/z 270 and 271). It is possible to determine concentrations as low as 1 nmol l-1 (0.3 ng ml-1) in 1 ml of sample with relative standard deviation of less than 10%.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7284572     DOI: 10.1002/bms.1200080708

Source DB:  PubMed          Journal:  Biomed Mass Spectrom        ISSN: 0306-042X


  9 in total

1.  The effect of hydralazine on steady-state plasma concentrations of metoprolol in pregnant hypertensive women.

Authors:  S Lindeberg; B Holm; P Lundborg; C G Regårdh; B Sandström
Journal:  Eur J Clin Pharmacol       Date:  1988       Impact factor: 2.953

2.  Pharmacokinetics of metoprolol in healthy, elderly, non-smoking individuals after a single dose and two weeks of treatment.

Authors:  M Larsson; S Landahl; P Lundborg; C G Regårdh
Journal:  Eur J Clin Pharmacol       Date:  1984       Impact factor: 2.953

3.  Pharmacokinetics of metoprolol and its metabolite alpha-OH-metoprolol in healthy, non-smoking, elderly individuals.

Authors:  C G Regårdh; S Landahl; M Larsson; P Lundborg; B Steen; K J Hoffmann; P O Lagerström
Journal:  Eur J Clin Pharmacol       Date:  1983       Impact factor: 2.953

4.  The pharmacokinetics of metoprolol and its metabolites in dialysis patients.

Authors:  K U Seiler; K J Schuster; G J Meyer; W Niedermayer; O Wassermann
Journal:  Clin Pharmacokinet       Date:  1980 Mar-Apr       Impact factor: 6.447

5.  Pharmacokinetics of metoprolol in patients with hepatic cirrhosis.

Authors:  C G Regårdh; L Jordö; M Ervik; P Lundborg; R Olsson; O Rönn
Journal:  Clin Pharmacokinet       Date:  1981 Sep-Oct       Impact factor: 6.447

6.  The effect of impaired renal function on the plasma concentration and urinary excretion of metoprolol metabolites.

Authors:  K J Hoffmann; C G Regårdh; M Aurell; M Ervik; L Jordö
Journal:  Clin Pharmacokinet       Date:  1980 Mar-Apr       Impact factor: 6.447

7.  Disposition of the adrenergic blocker metoprolol and its metabolite OH-metoprolol in maternal plasma, amniotic fluid and capillary blood of the neonate.

Authors:  S Lindeberg; P Lundborg; C G Regårdh; B Sandström
Journal:  Eur J Clin Pharmacol       Date:  1987       Impact factor: 2.953

8.  Plasma levels and beta-blocking effect of alpha-hydroxymetoprolol--metabolite of metoprolol--in the dog.

Authors:  C G Regårdh; L Ek; K J Hoffmann
Journal:  J Pharmacokinet Biopharm       Date:  1979-10

9.  Pharmacokinetic and pharmacodynamic properties of metoprolol in patients with impaired renal function.

Authors:  L Jordö; P O Attman; M Aurell; L Johansson; G Johnsson; C G Regårdh
Journal:  Clin Pharmacokinet       Date:  1980 Mar-Apr       Impact factor: 6.447

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.